cigna glp-1 coverage news Does cover Wegovy, Ozempic, Mounjaro & Zepbound? Cigna Wins First Cir. Bias
Description
Neeland, Ian J., et al
In the ATTAIN-2 trial, participants with both obesity and type 2 diabetes lost an average of 10.5% body weight on the highest dose while achieving HbA1c reductions of 1.8 percentage points
2007 Jul;30(7):1709-16
The latter circumstance is what allowed for the rise of GLP-1 compounding
106 Two additional clinical trials are being conducted to gather more data on adverse effects in different situations of liver injury, and a phase 2 trial investigating treatment effects for MASH with fibrosis based on histological assessment is ongoing (NCT05877547)
